Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Person

Peter A. Jones

Tracked across 1 events · 6 articles · First seen Sep 21, 2026 · Last active Sep 23, 2026

Sentiment
5
Attention
1
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
1 5
Tech
The phase 2 EVITA trial, a randomized, double-blind, placebo-controlled study, tested whether high-dose oral vitamin C (1000 mg/day for 12 months) could benefit patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies, conditions…
Impact: Co-senior author of the EVITA trial who voiced cautious optimism about vitamin C for intercepting leukemia development.
Sep 21, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Peter A. Jones live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.